BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 28524746)

  • 21. MOG-IgG in primary and secondary chronic progressive multiple sclerosis: a multicenter study of 200 patients and review of the literature.
    Jarius S; Ruprecht K; Stellmann JP; Huss A; Ayzenberg I; Willing A; Trebst C; Pawlitzki M; Abdelhak A; Grüter T; Leypoldt F; Haas J; Kleiter I; Tumani H; Fechner K; Reindl M; Paul F; Wildemann B
    J Neuroinflammation; 2018 Mar; 15(1):88. PubMed ID: 29554927
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Income in Multiple Sclerosis Patients with Different Disease Phenotypes.
    Kavaliunas A; Manouchehrinia A; Danylaite Karrenbauer V; Gyllensten H; Glaser A; Alexanderson K; Hillert J
    PLoS One; 2017; 12(1):e0169460. PubMed ID: 28081163
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Progression rates and sample size estimates for PPMS based on the CLIMB study population.
    Raghavan K; Healy BC; Carruthers RL; Chitnis T
    Mult Scler; 2015 Feb; 21(2):180-8. PubMed ID: 25070676
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Natural history comparisons of primary and secondary progressive multiple sclerosis reveals differences and similarities.
    Tremlett H; Zhao Y; Devonshire V;
    J Neurol; 2009 Mar; 256(3):374-81. PubMed ID: 19308306
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Voxel-based assessment of differences in damage and distribution of white matter lesions between patients with primary progressive and relapsing-remitting multiple sclerosis.
    Di Perri C; Battaglini M; Stromillo ML; Bartolozzi ML; Guidi L; Federico A; De Stefano N
    Arch Neurol; 2008 Feb; 65(2):236-43. PubMed ID: 18268194
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The natural history of primary progressive multiple sclerosis: insights from the German NeuroTransData registry.
    Braune S; Bluemich S; Bruns C; Dirks P; Hoffmann J; Heer Y; Rouzic EM; Bergmann A;
    BMC Neurol; 2023 Jul; 23(1):258. PubMed ID: 37407914
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Rao's Brief Repeatable Battery in the study of cognition in different multiple sclerosis phenotypes: application of normative data in a Serbian population.
    Dackovic J; Pekmezovic T; Mesaros S; Dujmovic I; Stojsavljevic N; Martinovic V; Drulovic J
    Neurol Sci; 2016 Sep; 37(9):1475-81. PubMed ID: 27207679
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of antioxidant parameters of multiple sclerosis patients' serum according to the disease course.
    Nowak-Kiczmer M; Niedziela N; Zalejska-Fiolka J; Adamczyk-Sowa M
    Mult Scler Relat Disord; 2023 Sep; 77():104875. PubMed ID: 37454567
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical predictors of disease progression in a cohort of Tunisian progressive Multiple Sclerosis.
    Souissi A; Mrabet S; Nasri A; Ben Djebara M; Gargouri A; Kacem I; Gouider R
    Mult Scler Relat Disord; 2021 Nov; 56():103232. PubMed ID: 34619488
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interferon beta for primary progressive multiple sclerosis.
    Rojas JI; Romano M; Ciapponi A; Patrucco L; Cristiano E
    Cochrane Database Syst Rev; 2009 Jan; (1):CD006643. PubMed ID: 19160292
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A significant decrease in diagnosis of primary progressive multiple sclerosis: A cohort study.
    Westerlind H; Stawiarz L; Fink K; Hillert J; Manouchehrinia A
    Mult Scler; 2016 Jul; 22(8):1071-9. PubMed ID: 27072687
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Late onset multiple sclerosis: Is it really late onset?
    Roohani P; Emiru T; Carpenter A; Luzzio C; Freeman J; Scarberry S; Beaver G; Davidson L; Parry G
    Mult Scler Relat Disord; 2014 Jul; 3(4):444-9. PubMed ID: 25877055
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical and laboratory features of primary progressive and secondary progressive MS.
    Bashir K; Whitaker JN
    Neurology; 1999 Sep; 53(4):765-71. PubMed ID: 10489038
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comparison of serum inflammatory parameters in progressive forms of multiple sclerosis.
    Nowak-Kiczmer M; Niedziela N; Czuba ZP; Sowa P; Wierzbicki K; Lubczyński M; Adamczyk-Sowa M
    Mult Scler Relat Disord; 2023 Nov; 79():105004. PubMed ID: 37738756
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Different cognitive profiles of Brazilian patients with relapsing-remitting and primary progressive multiple sclerosis.
    Rodrigues DN; Paes RA; Vasconcelos CC; Landeira-Fernandez J; Alvarenga MP
    Arq Neuropsiquiatr; 2011 Aug; 69(4):590-5. PubMed ID: 21877025
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical and demographic characteristics of primary progressive multiple sclerosis in Argentina: Argentinean registry cohort study (RelevarEM).
    Alonso R; Quarracino C; Eizaguirre B; Cohen L; Silva B; Pita C; Rojas JI; Pappolla A; Miguez J; Patrucco L; Cristiano E; Vrech C; Volman G; Silva E; Barboza A; Deri N; Tkachuk V; Zanga G; Tavolini D; Saladino ML; Luetic G; Menichini ML; Carnero Contentti E; López P; Steinberg J; Divi P; Hryb J; Alves Pinheiro A; Carra A; Balbuena ME; Lázaro L; Fernández Liguori N; Garcea O;
    Neurol Sci; 2020 Nov; 41(11):3329-3335. PubMed ID: 32840711
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differences in cognitive impairment of relapsing remitting, secondary, and primary progressive MS.
    Huijbregts SC; Kalkers NF; de Sonneville LM; de Groot V; Reuling IE; Polman CH
    Neurology; 2004 Jul; 63(2):335-9. PubMed ID: 15277630
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gene expression and genotyping studies implicate the interleukin 7 receptor in the pathogenesis of primary progressive multiple sclerosis.
    Booth DR; Arthur AT; Teutsch SM; Bye C; Rubio J; Armati PJ; Pollard JD; Heard RN; Stewart GJ;
    J Mol Med (Berl); 2005 Oct; 83(10):822-30. PubMed ID: 16075257
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 1H MRSI comparison of white matter and lesions in primary progressive and relapsing-remitting MS.
    Suhy J; Rooney WD; Goodkin DE; Capizzano AA; Soher BJ; Maudsley AA; Waubant E; Andersson PB; Weiner MW
    Mult Scler; 2000 Jun; 6(3):148-55. PubMed ID: 10871825
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The natural history of early versus late disability accumulation in primary progressive MS.
    Koch MW; Greenfield J; Javizian O; Deighton S; Wall W; Metz LM
    J Neurol Neurosurg Psychiatry; 2015 Jun; 86(6):615-21. PubMed ID: 25091366
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.